Business
Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023
Presentation to take place on June 1 from 10:30 a.m. to 12:00 p.m. EDT at the Yale School of Management NEW HAVEN, Conn., May 9, 2023 /PRNewswire/ -- Trevi
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Presentation to take place on June 1 from 10:30 a.m. to 12:00 p.m. EDT at the Yale School of Management\nNEW HAVEN, Conn., May 9, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced its participation at the upcoming Yale Innovation Summit taking place from May 31 – June 1 at the Yale School of Management. The Company will present on its differentiated central and peripheral mechanism in cough and the potential broad translatability across cough indications. \n\n \n \n \n \n \n \n\n \nTrevi's executives will be joined by one of the thought leaders in cough, Peter Dicpinigaitis, MD. Dr. Dicpinigaitis is a Professor of Medicine, Albert Einstein College of Medicine, Division of Critical Care Medicine, Montefiore Medical Center, Director, Montefiore Cough Center and Editor-in-Chief, LUNG. Dr. Dicpinigaitis will discuss the various central and peripheral pathways in cough and why a centrally active mechanism is generating such interest. Trevi will also share insights on the patient and commercial potential of Haduvio with additional details from its physician and payer market research across chronic cough indications. There will be a Q&A session at the end of the presentation.\nFor more information about the conference and to attend the presentation, please use the following link: https://ventures.yale.edu/community/yale-innovation-summit\nConference Details\nYale Innovation Summit (May 31-June 1)Presenters: Jennifer Good, President and CEO of Trevi Therapeutics, Farrell Simon, Chief Commercial Officer of Trevi Therapeutics, and Peter Dicpinigaitis, MD, Professor of Medicine, Albert Einstein College of Medicine, Division of Critical Care Medicine, Montefiore Medical Center, Director, Montefiore Cough Center and Editor-in-Chief, LUNGPresentation: Thursday, June 1, 10:30 AM-12 PM ETRegistration: Investors and analysts can register to attend the in-person event by using the following link: https://ventures.yale.edu/yale-innovation-summit\nA recording of the webcast will be available in the 'Investors & News' section on the Company's website at www.TreviThera...